Products> Pharmaceutical Products> Diabetes> Metformin Hydrochloride Tablets-Diabetes Treatment
Metformin Hydrochloride Tablets-Diabetes Treatment
Metformin Hydrochloride Tablets-Diabetes Treatment
Metformin Hydrochloride Tablets-Diabetes Treatment
Metformin Hydrochloride Tablets-Diabetes Treatment

Metformin Hydrochloride Tablets-Diabetes Treatment

Get Latest Price
    Share:
    • Payment Type: L/C,T/T
    • Incoterm: FOB,CFR,CIF,FCA,CPT
    • Transportation: Ocean,Air
    Supply Ability & Additional Information
    Additional Information

    TransportationOcean,Air

    Place of OriginChina

    Payment TypeL/C,T/T

    IncotermFOB,CFR,CIF,FCA,CPT

    Product Attributes

    Model No.NK-009

    BrandPenglai Nuokang

    ApplicationsFor type 2 diabetes whose blood sugar is not controlled by diet and physical exercise.

    Usage & DosageStart with a small dose and gradually increase the dose

    Package TypeCarton

    FormTablets

    Product Description

    Background:

    As one of Diabetes Management Solutions, Metformin Hydrochloride Tablets stand as a cornerstone, offering a lifeline to millions navigating the complex landscape of glucose regulation. Comprising the active ingredient metformin, these tablets have become a frontline therapy for individuals with type 2 Diabetes, forging a path towards improved glycemic control. The journey of Metformin Hydrochloride Tablets from scientific discovery to widespread clinical use is a testament to their efficacy and pivotal role in the evolving narrative of diabetes care.

    Metformin, a biguanide derivative, exerts its therapeutic influence by targeting key mechanisms of glucose metabolism. It reduces hepatic glucose production, enhances insulin sensitivity in peripheral tissues, and slows down glucose absorption in the gastrointestinal tract. This multifaceted approach addresses the core defects in type 2 diabetes, making Metformin Hydrochloride Tablets a versatile and comprehensive choice to Lower Blood Sugar.

    Metformin Hydrochloride Tablets are not merely glucose regulators; they extend their benefits beyond glycemic control. Research indicates potential cardiovascular benefits, with metformin demonstrating a positive impact on lipid profiles and reducing the risk of cardiovascular events. This dual-action aspect positions Metformin Hydrochloride Tablets as agents not only addressing the symptoms of diabetes but also mitigating the long-term cardiovascular risks associated with the condition.

    The user-friendly nature of Metformin Hydrochloride Tablets contributes to their popularity among individuals managing diabetes. The oral administration, often initiated at a low dose and gradually titrated, fosters patient adherence. This simplicity aligns with the principles of patient-centered care, recognizing the importance of treatment regimens that seamlessly integrate into individuals' daily lives.

    Safety considerations play a paramount role in the widespread acceptance of Metformin Hydrochloride Tablets. Known for their favorable safety profile, these tablets are generally well-tolerated. The risk of hypoglycemia, a common concern in diabetes management, is minimal with metformin alone, contributing to a sense of stability for patients navigating the intricacies of glucose control.

    Diabetes Products-Metformin Hydrochloride Tablets

    In order to reduce the occurrence of gastrointestinal complications, and also to use the smallest dose of the drug so that the patient's blood glucose is sufficient to control, it should be taken starting with a small dose and gradually increasing the dose.

    During the initiation of treatment and dose adjustment (see Recommended Medication Plan), the measurement of fasting blood glucose can be used to determine the therapeutic response of this product, as well as to determine the patient's minimum effective dose. Thereafter, glycated hemoglobin should be measured every three months. The goal of treatment, whether alone or in combination, is to reduce fasting blood glucose and glycosylated hemoglobin levels to normal or near-normal levels using the lowest effective dose.
    A medication plan is recommended
    normal renal function (eGFR≥90 mL/min/1.73 m2):
     Monotherapy and in combination with sulfonylureas
    Oral, adults and children start with 0.25 g each time, 2~3 times a day, and gradually increase the dose according to the efficacy after 10-15 days, and the maximum recommended dose is 2g per day. When taken with meals, gastrointestinal reactions may be reduced.
    In combination with sulfonylureas
     If the patient does not respond after several weeks of taking the maximum recommended dose of this product, the gradual addition of sulfonylurea oral hypoglycemic drugs while maintaining the maximum dose of therapy should be considered, unless the patient has a primary or secondary failure of the sulfonylurea. Only clinical and pharmacokinetic data are available on the interaction between metformin and glibenclamide (euglycemic reduction).
    Combined with this product and sulfonylureas, satisfactory blood sugar control can be achieved by adjusting the dose of the two drugs. In combination with this product, the risk of hypoglycemia with sulfonylureas persists or even increases, and appropriate prevention should be carried out.
     If the patient cannot control blood glucose satisfactorily for 1 to 3 months after combining the maximum dose of this product with the largest dose of oral sulfonylurea therapy, it is necessary to consider changing the treatment method, including this product combined with insulin therapy or insulin alone.
    In combination with insulin
     When starting to add this product, the dose of insulin can be maintained. The starting dose of this product in patients treated with insulin should be 0.5g, 1 time / day. If the patient's response is inadequate, 0.5 g is increased after 1 week, and thereafter 0.5 g can be increased weekly until satisfactory glycaemic control is achieved. The recommended maximum daily dose is 2 g. When the fasting blood glucose of patients who use this product in combination with insulin drops below 120mg/dL, it is recommended to reduce the insulin dose by 10%~25%. Adjustments should be continued or as directed by a physician in response to a decrease in blood glucose.
    Dose adjustment in adults with impaired renal function
    eGFR≥60 mL/min/1.73m2 does not need to adjust the dose, eGFR 45~59 mL/min/1.73m2 is reduced, eGFR<45 mL/min/1.73m2 is prohibited.
    GET IN TOUCH
    If you have any questions our products or services,feel free to reach out to us.Provide unique experiences for everyone involved with a brand.we’ve got preferential price and best-quality products for you.
    * Please fill in the information
    * Please fill in your e-mail
    * Please fill in the content
    Category: Diabetes
    Products> Pharmaceutical Products> Diabetes> Metformin Hydrochloride Tablets-Diabetes Treatment
    Send Inquiry
    *
    *
    *

    We will contact you immediately

    Fill in more information so that we can get in touch with you faster

    Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

    Send